Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHIMERIX INCCMRX · Entity 80651 | Director | May 17, 2018 | May 21, 2018 |
| HYPERION DEFI, INC.EYEN · Entity 7220 | Director | November 17, 2021 | November 22, 2021 |
| Jasper Therapeutics, Inc.AMHCU · Entity 7588 | Director | November 19, 2019 | November 19, 2019 |
| Kindred Biosciences, Inc.KIN · Entity 135544 | Director | January 20, 2021 | January 22, 2021 |
| SOLENO THERAPEUTICS INCSLNO · Entity 46432 | Director | June 06, 2024 | June 10, 2024 |
| Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169 | Director | June 25, 2018 | June 27, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHIMERIX INC
Report date May 17, 2018 · Filed May 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees | 123,167 |
Reported balance
After 2018-05-17 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-05-17 · Sale · Disposed 30,000 · Balance 123,167 F1: The range of sale prices received is $4.73 to $4.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees | 108,167 |
Reported balance
After 2018-05-18 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-05-18 · Sale · Disposed 15,000 · Balance 108,167 F2: The range of sale prices received is $4.76 to $4.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 12,905 |
Reported balance
Holding disclosure · report date 2018-05-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 12,905 |
Filing footnotes · ownership attribution and instrument terms
F1: The range of sale prices received is $4.73 to $4.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
F2: The range of sale prices received is $4.76 to $4.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
HYPERION DEFI, INC.
Report date November 17, 2021 · Filed November 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001SEC Table I · non-derivative | Direct | 382,706 |
Reported balance
After 2021-11-17 transaction · row 1
1 source rowRow 1 · 2021-11-17 · Grant · Acquired 6,963 · Balance 382,706 F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2031-11-17 | Direct | 9,653 |
Reported balance
After 2021-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-17 · Grant · Acquired 9,653 · Balance 9,653 F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
Jasper Therapeutics, Inc.
Report date November 19, 2019 · Filed November 19, 2019
This filing explicitly reported no securities owned.
Kindred Biosciences, Inc.
Report date January 20, 2021 · Filed January 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2031-01-19 | Direct | 49,000 |
Reported balance
After 2021-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-20 · Grant · Acquired 49,000 · Balance 49,000 F1: The option will vest in four equal quarterly installments from the option grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in four equal quarterly installments from the option grant date.
SOLENO THERAPEUTICS INC
Report date June 06, 2024 · Filed June 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 193,066 |
Reported balance
After 2024-06-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 6,500 · Balance 193,066 F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. F2: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 21,789 |
Reported balance
Holding disclosure · report date 2024-06-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 21,789 F3: The shares are held by Mildred Mario Nonexempt Trust, of which the Reporting Person is a co-trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date.
F2: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3: The shares are held by Mildred Mario Nonexempt Trust, of which the Reporting Person is a co-trustee.
Tonix Pharmaceuticals Holding Corp.
Report date June 25, 2018 · Filed June 27, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectBy Ernest and Mildred Mario Revocable Trust | 50,000 |
Reported balance
After 2018-06-25 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-06-25 · Purchase · Acquired 16,500 · Balance 50,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.46 to $4.52 per share, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp. ("Tonix"), any security holder of Tonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.46 to $4.52 per share, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp. ("Tonix"), any security holder of Tonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 62,884 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 4,908 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.50 · Expires 2024-07-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 20,700 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.16 · Expires 2025-06-17 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.98 · Expires 2026-06-15 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.04 · Expires 2027-06-14 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 10,500 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-20 · Disposition to issuer · Disposed 300 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-20 · Disposition to issuer · Disposed 970 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
F2: This option was fully exercisable.
F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2016 Filed Oct 31, 2016 16:34 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock Purchase Warrant · Derivative | 100,000 | Not disclosed Strike: $0.63 | Not disclosed |
DisclosureSEC source: 0001615774-16-007908 · s104483_form4.xml · derivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires 2021-10-31 F1 · price: Included in the purchase of 100,000 Units at a price of $0.55 per Unit. Each Unit consisted of one share of common stock and one warrant exercisable immediately for one-half (0.50) share of common stock at an exercise price of $0.63 per share. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 16:34 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001615774-16-007908 · s104483_form4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,724 F1 · price: Included in the purchase of 100,000 Units at a price of $0.55 per Unit. Each Unit consisted of one share of common stock and one warrant exercisable immediately for one-half (0.50) share of common stock at an exercise price of $0.63 per share. Read SEC document |
| October 06, 2016 Filed Oct 11, 2016 06:20 UTC | SOLENO THERAPEUTICS INC CAPN · Entity 46432 | GrantCommon Stock | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-031495 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,779,262 Read SEC document |
| September 23, 2016 Filed Sep 26, 2016 16:08 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 15,000 | $109.42 | $1,641,300.00 |
DisclosureSEC source: 0001209191-16-142766 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,058 Read SEC document |
| September 13, 2016 Filed Sep 14, 2016 18:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 100,000 | $0.79 | $79,180.00 |
DisclosureSEC source: 0001615774-16-007184 · s104124_form4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,724 F1 · price: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $0.791817611. The range of purchase prices on the transaction date was $0.7801 to $0.80 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Read SEC document |
| April 04, 2016 Filed Jan 31, 2017 16:23 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GiftCommon Stock | 4,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006367 · doc5.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,058 Read SEC document |
| February 25, 2016 Filed Mar 9, 2018 15:32 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001750 · s109297_form4.xml · derivative · entry 8 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On February 25, 2015, the reporting person was granted 600 restricted stock units, vesting in on the first anniversary of the grant date. F4 · derivative.expiration_date: On February 25, 2015, the reporting person was granted 600 restricted stock units, vesting in on the first anniversary of the grant date. Read SEC document |
| February 25, 2016 Filed Mar 9, 2018 15:32 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionCommon Stock, $0.001 par value | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001750 · s109297_form4.xml · nonDerivative · entry 5 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.